07Jun 2021
A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis

A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis

Infection and increased systemic inflammation cause organ dysfunction and death in patients with decompensated cirrhosis. Preclinical studies provide support for an antiinflammatory role of albumin, but confirmatory large-scale clinical trials are lacking. Whether targeting a serum albumin level of 30 g per liter or greater in these patients with repeated daily infusions of 20% human albumin solution, as compared with standard care, would reduce the incidences of infection, kidney dysfunction, and death is unknown.

  • #family health

Like

Save

Share